Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.

Abstract: The present disclosure provides for a recycled golf ball vending machine having a housing with a bottom retrieval chamber and a plurality of shelves disposed above the retrieval chamber. Each shelf includes at least a single coiled wire and at least two opposing coiled wires. The recycled golf ball vending machine includes at least a first transparent cylindrical container having a plurality of recycled golf balls positioned upright within the single coiled wire. The recycled golf ball vending machine further includes a first transparent clamshell container having a first predetermined number of recycled golf balls positioned between the two opposing coiled wires. A payment mechanism activates an instruction mechanism upon a receipt of a payment by a user, which in turn rotates the single coiled wire or the at least two coiled wires.

Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Disclosed herein is an engineered polypeptide comprising (i) a payload polypeptide, and (ii) a wild-type or engineered ?-factor prepro sequence, where the wild-type or engineered ?-factor prepro sequence is operably linked to the payload polypeptide. Also provided herein are polynucleotides encoding an engineered polypeptide of the present disclosure, as well as compositions comprising such polynucleotides or engineered polypeptides of the present disclosure. Methods of making and using the disclosed polypeptides, polynucleotides and compositions are also provided.

Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

Abstract: Nucleic acid expression systems for delivery of RNA oligonucleotides to target cells and methods of using the same are provided herein. For example, in some embodiments, a nucleic acid expression system comprises: (i) an RNA oligonucleotide comprising a payload sequence (e.g., a Myc inhibitor), and (ii) an RNA oligonucleotide comprising a sequence that encodes a US11 polypeptide. Provided herein are also pharmaceutical compositions comprising an RNA oligonucleotide comprising a payload sequence that encodes a dominant negative variant of a Myc polypeptide or portions thereof, and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.

Abstract: Nucleic acid expression systems are provided herein that include a first synthetic oligonucleotide comprising a payload sequence and a second synthetic oligonucleotide comprising a sequence that encodes a helper polypeptide. Compositions (e.g., pharmaceutical compositions) comprising the nucleic acid expression systems as well as methods of using the same are also provided herein.

Abstract: A self-extracting service module for piping infrastructures comprises a platform on which is mounted equipment for controlling and or monitoring the flow of liquid or gaseous media throughout the piping infrastructures. A first remote-controllable pipe coupling system is interconnected with the equipment inlet and a second pipe coupling system is interconnected to the equipment outlet. The platform is attached to actuators positioned near each corner of the platform. The actuators cooperate with at least one pressure-driven device. The service module is extracted from the piping infrastructure by isolating the equipment from the flow of liquid media after which, the pipe coupling systems are remotely disengaged from the piping infrastructure inlet and outlet. The actuators are operated to move the platform from within the piping infrastructure to a position where service work is easily performed on the equipment without the attendant hazards and constrictions associated with confined spaces.

Abstract: A self-extracting service module for piping infrastructures comprises a platform on which is mounted equipment for controlling and or monitoring the flow of liquid or gaseous media throughout the piping infrastructures. A first remote-controllable pipe coupling system is interconnected with the equipment inlet and a second pipe coupling system is interconnected to the equipment outlet. The pipe coupling systems are remotely manipulable for engaging and disengaging the equipment with piping infrastructure inlets and outlets. The platform is attached to actuators positioned near each corner of the platform. The service module is extracted from the piping infrastructure by first isolating the equipment from the flow of liquid media after which, the pipe coupling systems are remotely disengaged from the piping infrastructure inlet and outlet. The actuators are then operated to move the platform from within the piping infrastructure to a position where service work is easily performed on the equipment.